Microbial pathogenesis

Alopexx Announces Presentation at IDWeek 2023

Retrieved on: 
Mercredi, octobre 11, 2023
Deficit spending, Microbial pathogenesis, Alzheimer's disease, Hospital, Cone Health Women's Hospital, Vaccination, Dementia, Brigham and Women's Hospital, Disease, Mouse, Assistant, AD, Human, Parasitism, Research, Pharmaceutical industry, MD, Medicine

CAMBRIDGE, Mass., Oct. 11, 2023 /PRNewswire/ -- Alopexx, Inc., a clinical stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal and parasitic infections, today announced that Colette Cywes-Bentley, Ph.D., Assistant Professor of Medicine at Brigham and Women's Hospital, is scheduled to present pre-clinical data at IDWeek 2023's Microbial Pathogenesis of Alzheimer's Disease symposium being held October 11-15, 2023 in Boston, MA.

Key Points: 
  • Dr. Colette Cywes-Bentley will present pre-clinical data on the molecular mechanisms of microbiota-driven neuroinflammation and the therapeutic potential of targeting PNAG in the treatment and prevention of Alzheimer's Disease.
  • The presentation will discuss the results evaluating the role of targeting PNAG utilizing Alopexx's vaccine, AV0328 and monoclonal antibody F598.
  • Her research has shown that microbial fragments containing PNAG are present in the brains of mice and humans with Alzheimer's disease.
  • In murine models of Alzheimer's Disease, vaccination with Alopexx's AV0328 vaccine is able to prevent cognitive decline.

Infectious Diseases Society of America Foundation Announces Applications for Microbial Pathogenesis in Alzheimer's Research Grant

Retrieved on: 
Lundi, septembre 26, 2022
Mitsubishi Electric America Foundation, MD, Disease, Research, Infectious Diseases Society of America, Program, Microbial pathogenesis, Physician, Pathology, Foundation, Doctor of Philosophy, Neurology, Pathogenesis, CFRE, Microbiology, Education, Infection, Pharmaceutical industry, Alzheimer's disease

ARLINGTON, Va., Sept. 26, 2022 /PRNewswire/ -- The Infectious Diseases Society of America Foundation is now accepting applications for the Microbial Pathogenesis in Alzheimer's Disease Grant, a program that awards grants totaling $2.3 million to researchers investigating a possible link between infectious diseases and Alzheimer's. Applications are due October 30, 2022.

Key Points: 
  • Grant application period for innovative research that advances the field of microbial triggers for Alzheimer's disease open through October 30, 2022
    ARLINGTON, Va., Sept. 26, 2022 /PRNewswire/ -- The Infectious Diseases Society of America Foundation is now accepting applications for the Microbial Pathogenesis in Alzheimer's Disease Grant, a program that awards grants totaling $2.3 million to researchers investigating a possible link between infectious diseases and Alzheimer's.
  • Founded in 2018 by the IDSA Foundation, the Microbial Pathogenesis in Alzheimer's Disease Grant promotes novel research into the field of microbial triggers for the Alzheimer's disease by examining potential correlations between infectious agents or microbial communities and the disease.
  • To apply or learn more about the 2022 Microbial Pathogenesis in Alzheimer's Disease Research Grant, visit idsafoundation.org/alz-research-grant/ .
  • IDSA Foundation was founded in 2001 as the charitable arm of the Infectious Diseases Society of America.

More than $1.7 Million in IDSA Foundation Grant Funds Attracts Diverse Minds to Alzheimer's Research

Retrieved on: 
Mardi, janvier 18, 2022
Infectious Diseases Society of America, ID, Research, Mitsubishi Electric America Foundation, R01, Division, Pathogenesis, Board of directors, Johns Hopkins University, MBA, FIDSA, Microbial pathogenesis, Solution, Foundation, Health, Review, Infection, Program, Education, Doctor of Philosophy, MD, Opioid, Partnership, Board, Blog, Pharmaceutical industry, Broadcasting, Alzheimer's disease

This grant funding has ignited new research and also provides additional support to past successful applicants who have shown significant progress within their research."

Key Points: 
  • This grant funding has ignited new research and also provides additional support to past successful applicants who have shown significant progress within their research."
  • Laura Cox, PhD, a 2020 grant awardee and 2021 review panel member, recently received an R01 grant of $1.25 million to extend the pilot project she was able to start with the IDSA Foundation's grant funds.
  • Colette Cywes-Bentley, PhD, a 2021 grant awardee, received an additional $250,000 to expand research started with grant funds she received as an inaugural awardee of the grant program in 2018.
  • Through its work, the Foundation invests in the next generation of diverse ID leaders, supports innovative research and promotes advancements in patient care.